Salix Pharmaceuticals Receives Average Rating of “Buy” from Analysts (NASDAQ:SLXP)
Salix Pharmaceuticals (NASDAQ:SLXP) has been given an average recommendation of “Buy” by the nineteen ratings firms that are currently covering the company, AmericanBankingNews.com reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and twelve have assigned a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $133.86.
A number of analysts have recently weighed in on SLXP shares. Analysts at Zacks reiterated an “outperform” rating on shares of Salix Pharmaceuticals in a research note on Wednesday, August 13th. They now have a $153.00 price target on the stock. Separately, analysts at Jefferies Group downgraded shares of Salix Pharmaceuticals to a “neutral” rating in a research note on Friday, August 8th. Finally, analysts at Keefe, Bruyette & Woods reiterated an “outperform” rating on shares of Salix Pharmaceuticals in a research note on Friday, August 8th. They now have a $147.00 price target on the stock, down previously from $160.00.
Shares of Salix Pharmaceuticals (NASDAQ:SLXP) traded up 0.75% during mid-day trading on Monday, hitting $140.625. 176,852 shares of the company’s stock traded hands. Salix Pharmaceuticals has a 1-year low of $64.93 and a 1-year high of $141.81. The stock has a 50-day moving average of $133.1 and a 200-day moving average of $114.3. The company has a market cap of $8.956 billion and a price-to-earnings ratio of 154.57.
Salix Pharmaceuticals (NASDAQ:SLXP) last announced its earnings results on Thursday, August 7th. The company reported $1.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.69 by $0.10. The company had revenue of $382.00 million for the quarter, compared to the consensus estimate of $397.06 million. During the same quarter in the previous year, the company posted $0.87 earnings per share. The company’s revenue for the quarter was up 62.3% on a year-over-year basis. On average, analysts predict that Salix Pharmaceuticals will post $6.17 earnings per share for the current fiscal year.
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.